| sirolimus / Generic mfg. |
ACTRN12611001224910: REmoval Of Tacrolimus For Sirolimus Following Thymoglobulin Induction On The Development of REgulatory T Cells in Kidney Transplant Patients |
|
|
| Not yet recruiting | 4 | 30 | | | Department of Health, Genzyme Australia, Pfizer Australia | Development of circulating regulatory T cells, Kidney transplant function, complications and biopsy, Cardiovascular health, Metabolic outcomes (glucose abnormality), Clinical significant infections and cancers | | | | |
ChiCTR2200058886: Clinical study of sirolimus combined with prednisone vs prednisone as initial treatment for newly diagnosed moderate and severe chronic GVHD |
|
|
| Recruiting | 4 | 160 | | Sirolimus + Prednisone (or equivalent) ;Prednisone (or equivalent) | Medical Center of Hematology, Xinqiao Hospital of Army Medical University; Medical Center of Hematology, Xinqiao Hospital of Army Medical University, No | Chronic graft-versus-host-disease | | | | |
2009-016762-87: a randomized, open-label study to evaluate the safety and efficacy of delayed introduction of sirolimus and concomitant tacrolimus elimination in de novo renal allograft recipients |
|
|
| Ongoing | 4 | 100 | Europe | Tablet | OSPEDALE MAGGIORE DI MILANO (IRCCS) | no | | | | |
2004-004884-31: An open label, randomized pilot study evaluating the early conversion from calcineurin inhibitors to Rapamune in patients with impaired renal function following kidney transplantation |
|
|
| Ongoing | 4 | 60 | Europe | Tablet, Rapamune, Cellcept | Newcastle upon Tyne Hospitals NHS Trust | This study will be conducted in 60 established renal allograft recipients who have suffered from chronic renal failure of any cause. | | | | |
2008-000252-28: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplantation |
|
|
| Ongoing | 4 | 120 | Europe | Neoral, Coated tablet, Capsule, hard, Capsule, soft, Rapamune, Prograf, Neoral | Cambridge University Hospitals NHS Foundation Trust | Patients who have undergone liver transplantation and are infected with Hepatitis C virus. | | | | |
2013-004538-14: Trascriptomic differences between tacrolimus and mTOR inhibitors in the immunosuppressive treatment of renal transplantation Differenze transcrittomiche tra Tacrolimus e inibitori di mTOR nel trattamento immunosoppressivo del Trapianto renale |
|
|
| Ongoing | 4 | 40 | Europe | FK-506, Prolonged-release capsule, Tablet, ADVAGRAF 30CPS 3MG RP, ADVAGRAF 30CPS 0,5 MG RP, ADVAGRAF 60CPS 1MG RP, CERTICAN 60 cpr 0,75 mg, CERTICAN 60 cpr 0,25 mg, RAPAMUNE 100CPR RIV 1MG, RAPAMUNE 30CPR RIV 2MG, MYCOPHENOLATE MOFETIL 50CPR 500MG | Azienda Ospedaliera Universitaria Integrata Verona, Università di Verona | Renal Transplantation Trapianto renale, Renal Transplantation Trapianto renale, Not possible to specify | | | | |
ChiCTR-TRC-11001802: An Open Randomized Controlled Clinical Study on Sirolimus-Based Immunosuppression for replapse and metastasis of Liver Transplantation in the Presence of Extended Criteria for Hepatocellular Carcinoma |
|
|
| Completed | 4 | 60 | | tacrolimus ;sirolimus | The General Hospital of Chinese People's Armed Police Forces; The General Hospital of Chinese People’s Armed Police Forces, self-financing | liver transplantation; hepatocellular carcinoma | | | | |
2005-000855-14: Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor. |
|
|
| Ongoing | 4 | 65 | Europe | NA, NA, RAPAMUNE*1MG 100 CPR, RAPAMUNE*2MG 30 CPR, RAPAMUNE*OS 60 ML 1 MG, THYMOGLOBULINE*IV 1F 25MG +F, RAPAMUNE*1MG 100 CPR, RAPAMUNE*2MG 30 CPR, RAPAMUNE*OS 60 ML 1 MG, THYMOGLOBULINE*IV 1F 25MG +F | AZIENDA OSPEDALIERA DI PADOVA | Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. | | | | |
2004-005055-33: Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay immunosuppression in comparison to current standard immunosuppression (mycophenolate mofetil, tacrolimus and continued corticosteroids) in renal transplantation. |
|
|
| Ongoing | 4 | 180 | Europe | Zenapax, Cellcept, Prograf, Rapamune, Ro 24-7375, Ro 106-1443, Not available, Zenapax, Cellcept, Prograf, Rapamune, Zenapax, Cellcept, Prograf, Rapamune | Barts and the London NHS Trust | Renal Transplantation | | | | |
2005-003383-39: A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal. |
|
|
| Ongoing | 4 | 144 | Europe | Rapamune, Daclizumab, Rapamune, ZENAPAX, Rapamune, ZENAPAX | Roche Farma S.A. | Renal Transplant | | | | |
2005-000936-26: Sirolimus en el tratamiento de la nefropatía crónica del injerto demostrada histológicamente |
|
|
| Ongoing | 4 | 100 | Europe | Rapamune 1 mg Comprimidos Recubiertos, Rapamune 1mg Comprimidos Recubiertos, Rapamune 1mg Comprimidos Recubiertos | Wyeth Farma, S.A. | | | | | |
2004-004947-23: Efficacité de la rapamycine dans la prévention secondaire des cancers cutanés chez les transplantés rénaux. Etude ouverte randomisée Rapamycine vs anticalcineurines |
|
|
| Ongoing | 4 | 25 | Europe | Neoral, Rapamune, neoral, neoral 50MG, Rapamune 1 mg, Neoral 100mg, Rapamune 2 mg, neoral 50MG, Rapamune 1 mg, Neoral 100mg, Rapamune 2 mg | UF de méthodologie en recherche clinique, Hospices Civils de Lyon | To evaluate the impact of two imnosupressive regimens on the incidence of skin cancers among patients who has a first spinocellular skin cancer after renal transplantation | | | | |
2005-004509-27: Intérêt de la rapamicine (Rapamune(R)) pour la prévention secondaire des cancers cutanés chez les transplantés rénaux ayant présentant plus d\'un Carcinome Spinocellaire. |
|
|
| Ongoing | 4 | 25 | Europe | Neoral, Rapamune, neoral, Neoral 50 mg, rapamune 1mg, Neoral 100 mg, rapamune 2 mg, Neoral 50 mg, rapamune 1mg, Neoral 100 mg, rapamune 2 mg | Cliniques Hopitaux Universitaires NANTES, Hospices Civils de Lyon | To evaluate the impact of two immunosuppressive regimens on the incidence of skin cancers among patients who have had previously a first spinocellulaire skin cancer after transplantation | | | | |
2006-001265-41: A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody |
|
|
| Ongoing | 4 | 60 | Europe | Sirolimus, Sirolimus (Rapamune), Sirolimus (Rapamune) | Newcastle upon Tyne Hospitals NHS Trust | Kidney transplantation from non heart beating donors for end-stage renal disease | | | | |
2007-002763-27: A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts. |
|
|
| Ongoing | 4 | 100 | Europe | Sirolimus, Tacrolimus, Rapamune, Prograft, Rapamune, Prograft | Erasmus MC | Recipients of a renal allograft from a non-heart-beating donor, three months after transplantation. | | | | |
2006-004773-99: A RANDOMISED CONTROLLED TRIAL COMPARING THE USE OF SIROLIMUS BASED BIPHASIC IMMUNOSUPRESSION WITH MYFORTIC TO ALLOW EARLY CNI WITHDRAWAL IN RENAL TRNASPLANTATION |
|
|
| Ongoing | 4 | 42 | Europe | Rapamune, Rapamune, Prograf, Myfortic, Rapamune, Prograf, Myfortic | University Hospitals Leicester | Chronic Allograft Nephropathy | | | | |
2008-008895-15: Influence de l\'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal |
|
|
| Ongoing | 4 | 30 | Europe | sirolimus, | Hospices Civils de Lyon | Transplantation rénale | | | | |
2009-010920-24: Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD) |
|
|
| Ongoing | 4 | 120 | Europe | RAPAMUNE 2 mg comprimidos recubiertos, RAPAMUNE 2 mg comprimidos recubiertos | Fundación para la Investigación Biomédica del Hospital Universitario La Paz | Poliquistosis Renal Autosómica Dominante (PQRAD) | | | | |
2010-022589-29: Study testing at how mTOR inhibiting drugs work in kidney cancer. |
|
|
| Ongoing | 4 | 20 | Europe | Rapamune, Afinitor, Rapamune, Afinitor, Rapamune, Afinitor | University of Oxford | Renal cancer | | | | |
C-STAR Trial, ChiCTR-TRC-12002999: Early Conversion from Tacrolimus to Sirolimus Based Therapy versus Tacrolimus Maintenance Therapy in Chinese Kidney Transplant Recipients |
|
|
| Completed | 4 | 250 | | transfer tacrolimus to SRL ;continue use tacrolimus | Kidney Disease Center, The First Affiliated Hospital of Zhejiang University; None, Hisun-Pfizer Pharmaceutical Co.,Itd. | Renal Transplantation | | | | |
2010-019337-10: Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta inmunosupresora libre de fármacos anticalcineurínicos frente a un regimen convencional (basado en fármacos anticalcineurinicos) en receptores de un trasplante renal de riesgo estándar. Estudio piloto abierto, aleatorizado (2:1), prospectivo y unicentrico para evaluar el rechazo agudo y la función renal de una pauta inmunosupresora libre de fármacos anticalcineurínicos frente a un regimen convencional (basado en fármacos anticalcineurinicos) en receptores de un trasplante renal de riesgo estándar. |
|
|
| Ongoing | 4 | 30 | Europe | MICOFENOLATO MOFETIL, TACROLIMUS, TIMOGLOBULINA 5mg/ml Polvo para solución para perfusión, PRIVIGEN 100 mg/ml solución para perfusión, RAPAMUNE 1 mg comprimidos recubiertos, SIMULECT 20 mg polvo y disolvente para sol. iny. o sol. para perfusión, CELLCEPT 250 MG CAPSULAS, CELLCEPT 500 MG COMPRIMIDOS, CELLCEPT 500MG, POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION, RAPAMUNE 1 mg/ml solución oral, TIMOGLOBULINA 5mg/ml Polvo para solución para perfusión, PRIVIGEN 100 mg/ml solución para perfusión, RAPAMUNE 1 mg comprimidos recubiertos, SIMULECT 20 mg polvo y disolvente para sol. iny. o sol. para perfusión, CELLCEPT 250 MG CAPSULAS, CELLCEPT 500 MG COMPRIMIDOS, CELLCEPT 500MG, POLVO PARA CONCENTRADO PARA SOL. PARA PERFUSION, RAPAMUNE 1 mg/ml solución oral | SERVICIO NEFROLOGIA HOSPITAL UNIVERSITARIO DE BELLVITGE, Pfizer, Behring | END STAGE RENAL DISEASE-KIDNEY TRANSPLANTATION INSUFICIENCIA RENAL TERMINAL- TRASPLANTE RENAL | | | | |
2005-004372-20: A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma. |
|
|
| Ongoing | 4 | 90 | Europe | Sirolimus, neoral, ciclosporin, Tacrolimus, Mycophenolate Mofetil, azathioprine, 12, | Oxford Radcliffe Hospitals NHS Trust | Cutaneous squamous cell carcinoma after kidney transplantation | | | | |
ChiCTR-IPR-16009451: The Efficacy and Safety of Low Dose IL-2 Conbined Rapamycin Therapy in Chinese Over-treated Patients with Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 4 | 60 | | IL-2 ;IL-2 and Rapamycin ;Glucocorticoids and DMARDs | the Second Hospital of Shanxi Medical University; the Second Hospital of Shanxi Medical University, Self support | Systemic Lupus Erythematosus | | | | |
ChiCTR-IPR-17010307: The efficacy and safety of rapamycin in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China |
|
|
| Recruiting | 4 | 300 | | Rapamycin ;conventional glucocorticoids and DMARDs | the Second Hospital of Shanxi Medical University; the Second Hospital of Shanxi Medical University, Self support | Rheumatoid Arthritis | | | | |
ChiCTR-IPR-17011566: The efficacy and safety of sirolimus in refractory rheumatoid arthritis: A multi-center randomized controlled trial in China |
|
|
| Recruiting | 4 | 300 | | Sirolimus ;Glucocorticoids and Immunosuppressant | the Second Hospital of Shanxi Medical University; the Second Hospital of Shanxi Medical University, Self support | Rheumatoid Arthritis | | | | |
ChiCTR-TRC-11001513: A randomized controlled trial of sirolimus-based immunosuppression versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma |
|
|
| Completed | 4 | 120 | | mTOR-inhibitor-free immunosuppression ;sirolimus-based immunosuppression | West China Hospital, Sichuan University; West China Hospital, Sichuan University, self-financial | Hepatocellular carcinoma | | | | |
2019-002240-24: Evolution of organ complications of diabetes mellitus after pancreas and kidney transplantation Vývoj orgánových komplikací diabetu po transplantaci ledviny a pankreatu |
|
|
| Not yet recruiting | 4 | 120 | RoW | Tablet, Capsule, Rapamune, Cellcept, Myfenax | Institut klinické a experimentální medicíny, Institut klinické a experimentální medicíny | Surgical complications (hernia) after simultaneous pancreas and kidney transplantation Chirurgické komplikace (zejména kýla) po kombinované transplantaci ledviny a slinivky, Risk of hernia in patients after pancreas and kidney transplantation Riziko vzniku kýly po transplantaci ledviny a slinivky, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
ChiCTR1900021896: Prospective study for pd-1 inhibitor combined with liquid biopsy ctDNA detection combined with targeted drugs in the treatment of advanced unresectable liver cancer patients |
|
|
| Recruiting | 4 | 50 | China | Once every 2 weeks Opdivo drug therapy, medicine according to the 3 mg/kg body weight calculation Opdivo dose, intravenous drug. Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apatinib and sirolimus.other drugs including COX2 inhibitor aspi ;The Keytruda drug treatment group will be given Keytruda drug treatment once every three weeks, with a dose of 200mg, usage and precautions the same as Opdivo drug. intravenous drug.Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apa | The Third Affiliated Hospital of Sun Yat-sen University ; The Third Affiliated Hospital of Sun Yat-Sen University, Researcher afford | hepatocelluar carcinoma | | | | |
ChiCTR1900021894: Prospective study of pd-1 inhibitor combined with liquid biopsy ctDNA detection combined with targeted drugs and hepatic arterial chemoembolization for the treatment of advanced unresectable liver cancer patients |
|
|
| Recruiting | 4 | 50 | China | Once every 2 weeks Opdivo drug therapy, medicine according to the 3 mg/kg body weight calculation Opdivo dose, intravenous drug. Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apatinib and sirolimus.other drugs including COX2 inhibitor aspi ;The Keytruda drug treatment group will be given Keytruda drug treatment once every three weeks, with a dose of 200mg, usage and precautions the same as Opdivo drug. intravenous drug.Using the technology of liquid biopsy ctDNA for gene mutation to screen suitable targeted drug including sorafenib, Lomatinib, Apa | The Third Affiliated Hospital of Sun Yat-sen University ; The Third Affiliated Hospital of Sun Yat-Sen University, Researcher afford | hepatocelluar carcinoma | | | | |
ChiCTR1800020355: Clinical study for sirolimus in the treatment of myelodysplastic syndrome in senile patients |
|
|
| Recruiting | 4 | 20 | | Take Sirolimus | The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, Dalian Medical Science Research Program | Myelodysplastic Syndrome | | | | |
ChiCTR1900024261: Efficacy and safety of sirolimus in new-onset rheumatoid arthritis: a prospective, double-blinded, randomized, placebo-controlled, monocentric study in China |
|
|
| Not yet recruiting | 4 | 60 | | methotrexate (7.5~15 mg/week)+ placbo (1 mg/d) ;sirolimus (1 mg/d) + methotrexate (7.5~15 mg/week) | The Second Hospital of Shanxi Medical University; The Second Hospital of Shanxi Medical University, North China Pharmaceutical Co.,Ltd. | rheumatoid arthritis | | | | |
BULK-STEMI, NCT04570345: 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI |
|
|
| Recruiting | 4 | 1002 | RoW | ticagrelor monotherapy, Study group, Aspirin with P2Y12 receptor inhibitor, Control group | Dong-A University | ST Elevation Myocardial Infarction | 08/21 | 08/22 | | |
ChiCTR1900020657: Dexamethasone and dexamethasone combined with sirolimus in the treatment of adult newly diagnosed ITP: a multicenter, randomized, controlled, open trial |
|
|
| Not yet recruiting | 4 | 160 | | dexamethasone combined with sirolimus ;dexamethasone | Department of Hematology, Xiniao Hospital; Department of Hematology, Xiniao Hospital, Clinical Founding | Adult newly diagnosed ITP | | | | |
2022-000617-13: prospective, randomized, controlled study evaluating the effect of conversion from tacrolimus treatment to mTor inhibitor-based immunosuppression + tacrolimus to boost conversion to positive SARS-CoV-2 serology after a fourth dose of the vaccine of SARS-CoV-2 mRNA in solid organ transplant recipients who have not previously responded. Un estudio prospectivo, aleatorizado y controlado que evalúa el efecto de la conversión del tratamiento de tacrolimus a la inmunosupresión basada en inhibidores de mTor + tacrolimus para reforzar laconversión a positivo e la serología del SARS-CoV-2 después de una cuarta dosis de la vacuna de ARNm del SARS-CoV-2 en pacientes receptores de trasplante de órgano sólido que no han respondido previamente. |
|
|
| Ongoing | 4 | 50 | Europe | Oral solution, Tablet, Capsule, hard, Rapamune, Myfortic, Cellcept | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine Se evalua la seroconversión tras el cambio de tratamiento de tacrolimus a tacrolimus + inhibidor de mTOR de los pacientes trasplantados de órgano sólido que no hayan respondido a las tres primeras dosis de la vacuna, Se evalúa si los pacientes crean anticuerpos contra la covid tras cambiar el tratamiento a tacrolimus + imTOR en pacientes trasplantados que no han respondido a las tres primeras dosis de la vacuna It's evaluated if patients create antibodies against covid after changing treatment to tacrolimus + imTOR in transplant patients who have not responded to the first three doses of the vaccine, Body processes [G] - Immune system processes [G12] | | | | |
NCT03500367: Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis |
|
|
| Recruiting | 4 | 25 | RoW | rapamycin | Peking Union Medical College Hospital | Uterine Fibroids | 06/22 | 12/22 | | |
ChiCTR1800017277: Efficacy and safety of early conversion of low dose calcineurin inhibitor combined with sirolimus to renal transplant patients: a multicenter randomized controlled trial |
|
|
| Recruiting | 4 | 750 | | Standard regimen treatment after renal transplantation ;After 4 weeks of standard treatment, renal transplant recipients were converted to low dose calcineurin inhibitor combined with sirolimus. | Beijing Chaoyang Hospital; Beijing Chaoyang Hospital, China International Foundation for Medical Exchange | renal transplantation | | | | |
NCT04177095: Immune Monitoring to Facilitate Belatacept Monotherapy |
|
|
| Completed | 4 | 17 | US | Allosure, donor-derived cell-free DNA (dd-cfDNA), Immunosuppression reduction, Belatacept, mycophenolate, sirolimus, everolimus, prednisone, Trugraf | Massachusetts General Hospital, Transplant Genomics, Inc., CareDx | Kidney Transplant Rejection, Immunosuppression | 09/21 | 06/23 | | |
NCT04448873: Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma |
|
|
| Completed | 4 | 30 | RoW | Sirolimus, Rapamycin | Children's Hospital of Fudan University | Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome | 02/23 | 07/23 | | |
TICO, NCT02494895: Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome ( Study) |
|
|
| Recruiting | 4 | 3056 | RoW | Ticagrelor monotherapy, Brilinta®, Ticagrelor with Aspirin DAPT(dual antiplatelet treatment) | Yonsei University | Acute Coronary Syndrome | 05/23 | 05/23 | | |
ChiCTR2200062308: Efficacy and safety of sirolimus in combination with low-dose tacrolimus in renal transplantation patients with BK virus infection |
|
|
| Not yet recruiting | 4 | 90 | | low-dose tacrolimus+MPA+prednison ;low-dose tacrolimus+sirolimus+prednison | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, None | Kidney transplantation | | | | |
ChiCTR2200066031: The Effect of Sirolimus in Treating IgA Nephropathy: a Single Center Prospective Exploratory Study |
|
|
| Recruiting | 4 | 12 | | Sirolimus: initial dose 1mg/d, target trough concentration 5-8μg/L, and supportive treatment | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-funding | IgA Nephropathy | | | | |
| Not yet recruiting | 4 | 100 | | Rapamycin is taken orally ;conventional IVF procedure | Shanxi Medical University; Shanxi Medical University, Reproductive and Genetic Research and Technology Team of Shanxi Province | Diminished Ovarian Reverse | | | | |
NCT05193565: Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients |
|
|
| Recruiting | 4 | 206 | RoW | Sirolimus, RaparoBell® Tab., Mycophenolate mofetil, Myrept® Cap./Tab. | Chong Kun Dang Pharmaceutical | Kidney Transplantation | 01/24 | 06/24 | | |
SDCMK, NCT06236022: The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus |
|
|
| Recruiting | 4 | 276 | RoW | Sirolimus | Tongji Hospital, Wuhan Central Hospital, Wuhan Fourth Hospital, Wuhan University | Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection | 12/28 | 12/28 | | |
ChiCTR2100045718: Clinical study of Ruxolitinib combined with Sirolimus in preventing Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | 4 | 48 | | Ruxolitinib combined with Sirolimus ;ciclosporin or tacrolimus | Sichuan Provincial People's Hospital, Affliated Hospital of University of Electronic Science and Technology of China; Sichuan Provincial People's Hospital, Affliated Hospital of University of Electronic Science and Technology of China, self-raised | Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation | | | | |
ChiCTR2200063697: once-daily immunosuppressive regimen in kidney transplant recipients |
|
|
| Not yet recruiting | 4 | 160 | | Tac-ER+SRL ;Tac+MPA | Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology; Level of the institution：, NO | kidney transplantation | | | | |
| Not yet recruiting | 4 | 36 | RoW | Sirolimus Oral Product, TORISEL, rapamycin, propranolol, xin de an (chinese name means making me comfortable) | Shanghai Children's Medical Center | Hemangioendothelioma of Liver | 06/24 | 06/25 | | |
ChiCTR2200065756: Clinical observation of Sirolimus tablets in the treatment of benign lymphatic endothelioma |
|
|
| Not yet recruiting | 4 | 8 | | Sirolimus tablets 0.8mg/m^2/ day | The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University, Clinical Research Fund of the Department | benign lymphatic endothelioma | | | | |
NCT04700709: Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients. |
|
|
| Not yet recruiting | 4 | 158 | RoW | Sirolimus Tab., RaparoBell® Tab., Mycophenolate Mofetil Cap./Tab., Myrept® Cap./Tab. | Chong Kun Dang Pharmaceutical | Kidney Transplantation | 12/24 | 01/25 | | |
ChiCTR2300074762: Research on the precise treatment strategy of benign metastatic leiomyoma |
|
|
| Not yet recruiting | 4 | 70 | | oral sirolimus ;Outpatient follow-up | Department of Obstetrics and Gynecology, Peking Union Medical College Hospital; Peking Union Medical College Hospital, National High Level Hospital Clinical Research Funding | benign metastatic leiomyoma | | | | |
ChiCTR2100046873: Study on the efficacy and safety of rapamycin (sirolimus) in the treatment of familial adenomatous polyposis |
|
|
| Recruiting | 4 | 20 | | Oral sirolimus | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-funded | Familial adenomatous polyposis | | | | |
ChiCTR2100052913: Efficacy and safety of mTORi in the treatment of secondary immune thrombocytopenia |
|
|
| Recruiting | 4 | 154 | | sirolimus and dexamethasone ;steroid | The Second Affiliated Hospital of Army Military Medical University; Department of Hematology, Second Affiliated Hospital of Army Military Medical University, No | secondary immune thrombocytopenia, sITP | | | | |
